Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tandem high-dose carboplatin-etoposide with peripheral blood stem-cell rescue in relapsed or refractory metastatic germ-cell tumors
2010-021898-36Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Nov 2010
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carboplatin and etoposide in germ cell tumor (GCT), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: 2-year progression-free survival. Started Nov 2010; status: completed.
02
Drugs
carboplatinetoposide
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on 2010-021898-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021898-36.